Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2014Expert Opinion on Investigational Drugs

Dinaciclib for the treatment of breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CCCarmen CriscitielloHumanitas UniversityGVGiulia VialeVita-Salute San Raffaele UniversityAEAngela EspósitoUniversity of Modena and Reggio Emilia

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Criscitiello et al. (2014) studied this question.

synapsesocial.com/papers/6a7996ba02ab7a73dd026e2dhttps://doi.org/10.1517/13543784.2014.948152
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors2012 · 232 citations
  2. 2A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days2006 · 264 citations